Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents.
Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an investigational treatment for male and female sexual dysfunction. Data from preclinical efficacy studies of PT-141 will be presented Saturday, October 27th, at the Female Sexual Function Forum (FSFF) Meeting in Boston, MA.
The studies were performed by Palatin scientists in collaboration with Concordia University in Montreal. Annette M. Shadiack, PhD, Director, Biological Research at Palatin, will present the results.
The studies objectives were to evaluate PT-141s ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141s effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents desire to copulate.
These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders said Dr. Shadiack.
Perry Molinoff, M.D., Executive Vice President of Research & Development of Palatin said, We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year.
Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 wa
Contact: Joan Kureczka